Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Next Previous
X
Search
Trial Profile

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Adrenocortical carcinoma; Advanced breast cancer; Appendiceal cancer; Basal cell cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Chordoma; Choriocarcinoma; Colon cancer; Colorectal cancer; Endometrial cancer; Extramammary Paget disease; Fibroma; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Gastrointestinal stromal tumours; Gestational trophoblastic disease; Giant cell tumours; Haemangiosarcoma; Head and neck cancer; Laryngeal cancer; Lung cancer; Nerve sheath neoplasms; Neuroblastoma; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Paraganglioma; Parathyroid cancer; Pelvic cancer; Peritoneal cancer; Perivascular epithelioid cell tumours; Phaeochromocytoma; Pharyngeal neoplasms; Pituitary cancer; Prostate cancer; Rectal cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Seminoma; Solid tumours; Squamous cell cancer; Teratoma; Thyroid cancer; Tracheobronchial cancer; Trophoblastic tumour; Urogenital cancer; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Acronyms DART

    • Most Recent Events

    • 04 Jun 2024 Results (n=487) evaluating mixed response and survival outcomes among patients with various tumors receiving dual checkpoint therapy, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2024 Results assessing associations between immune-related adverse events observed in the first cycle (6 weeks) of therapy were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 13 Dec 2023 Planned End Date changed from 31 Oct 2024 to 1 May 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top